Eva vergara
08/04/2021 9:00
Clarín.com
World
Updated 08/04/2021 9:29 AM
A new study by the Ministry of Health of
Chile
seems to
give some clues about the effectiveness of vaccines against the coronavirus.
And it showed positive results from those manufactured by different laboratories in terms of preventing serious cases and deaths.
The research, released on Tuesday,
showed a
5%
drop
in the effectiveness of the Chinese Sinovac vaccine in preventing symptomatic cases of Covid-19, while the US Pfizer vaccine decreased by 3%.
The
effectiveness to prevent death
remains virtually the same with Sinovac, while Pfizer showed an increase of 8.2% in the prevention of deaths, according to the report delivered by Dr. Rafael Araos, advisor to the Ministry and former head of its department of Epidemiology.
CASES
0.000.00000.000
per million inhab.
Xxxxx
DEATHS
00,0000,000
per million inhab.
Source:
Johns Hopkins
Chart:
Flourish
|
Infographic:
Clarín
Both vaccines maintain
high levels of effectiveness to prevent hospitalizations
and admission to Intensive Care Units (ICU).
The Ministry's analysis measured the effectiveness of
the most widely used immunizers in Chile, Sinovac and Pfizer,
exactly six months after the start of the massive Chilean vaccination plan on a sample that includes 8.6 million people inoculated with Sinovac and 4, 1 million with Pfizer.
In all cases, more than 14 days had elapsed since the second dose.
This is the third effectiveness study to be carried out in Chile, a country of 19 million inhabitants that is among the nations in the world with the highest percentage of vaccinated population.
The President of Chile, Sebastián Piñera and the Minister of Health, Enrique Paris.
Photo: DPA
As of July, 87% of the 15.2 million people seeking immunization had received the first dose and
80% had already completed the vaccination process.
Protection in numbers
Araos specified that
Sinovac is effective in 58.4% of cases to prevent
Covid-19
infection
(compared to the 63.6% effectiveness shown in June), avoids hospitalization in 86% (87%),
avoids in 90% admission to intensive care units
and prevents death in 86.4% of cases.
The Pfizer vaccine showed an effectiveness of 87.69% in the prevention of symptomatic Covid-19 (90.9%), maintains 97% to prevent hospitalization and 98% the arrival to the ICU, and
prevents death in 100% of the cases, an effectiveness that was 91.8% in June.
AstraZeneca
For the first time, the effectiveness of the British Swedish
AstraZeneca
vaccine was measured
in a sample of 2,720 people who were followed for the past two months.
According to the study, it prevented infections by 68.68% and
hospitalizations
, admission to intensive care and death
in
100%
.
Six months after the start of mass vaccination, Chile has shown a sharp decline in infected.
On Tuesday, it reported 616 new daily cases, a far cry from the 9,171 infected on April 9.
University students wait to receive a Covid vaccine at the Andrés Bello University in Santiago de Chile.
Photo: AP
Relief and reopening
The decrease in infections in the South American country led the government to gradually lift quarantines in its 346 communes, except for four.
The authorities now allow great mobility of those who verify with a card that they have completed their immunization process.
Restaurants, cinemas and even some discotheques were opened and the regions that exceeded 80% of vaccinated inhabitants can delay the curfew by two hours, which in the rest of the country applies from ten at night to five in the morning.
However, the authorities are alert to an eventual expansion of those infected with the contagious Delta variant.
On Monday it was reported that there are 59 infected by this variant, of which 55 correspond to people who returned from abroad or were narrow cases of them, and four are the result of community transmission.
Chile registers 1.6 million infected since the beginning of the pandemic, in March of last year, and more than 35,000 deaths.
Source: AP
CB
Look also
Chile recorded the lowest number of new coronavirus cases in 9 months
Alarm in Italy: Will a new variant of Covid resistant to all vaccines arrive?
